Marker Therapeutics Q3 2026 Results: Net Loss of $1.84M, Loss Narrows
Marker Therapeutics, Inc. reported financial results for the quarter ended September 30, 2026, highlighting continued progress in its clinical-stage cell therapy pipeline. The company maintained a net loss as it invests in R&D, with sufficient cash reserves to support operations into the following year.
- Key figure
- Net loss $1.84M